Overview
Public BiotechPhase 1ibogainepsilocybinDMTOtherHiring
Formed from the merger of ATAI Life Sciences and Beckley Psytech in November 2025. Developing BPL-003 (mebufotenin/5-MeO-DMT nasal spray) for treatment-resistant depression, with Phase 3 trials expected Q2 2026.
Visit WebsiteBerlin, Germany
$600M
Market Cap
2018
Founded
120
Employees
1
Open Roles
Open Positions(1)
Clinical Pipeline(4)
Completed·Phase 1·ibogaine
A Study of Oral Ibogaine in Opioid Withdrawal
DMX-1002Opiate Withdrawal Syndrome
Terminated·Phase 1·psilocybin
Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
PsilocybinShort Lasting Unilateral Neuralgiform Headache Attacks
Completed·Phase 1·DMT
Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects
5-MeO-DMTPharmacokinetics in Healthy Adults
Completed·Phase 1·Other
Single Ascending Dose Study With BPL-003 in Healthy Subjects
BPL-003Pharmacokinetics in Healthy Adults